News Announcement from Incubate Bio

Incubate Bio launches open source characterized targets database for drug sensitivity and target discovery in Ovarian cancer: ALaSCAdb

- *Starting with DDR pathways and PARP inhibitors*
- *Including in silico simulation results of the causal mechanisms*
- *Generated by the ALaSCA Cancer Model System using novel Causal AI algorithms and public datasets*

London, July 19, 2023 – Incubate Bio announces the release of ALaSCAdb, a characterized targets database for Ovarian cancer. ALaSCAdb has been developed specifically to enable rapid investigation and in silico experimentation to assist discovery and development of novel cancer therapies.

ALaSCAdb has been generated by the ALaSCA Cancer Model System, which is underpinned by a unique combination of a Large Language Model approach coupled with a powerful proven Causal AI engine. Together these allow ALaSCA to enable early-stage drug discovery groups to rapidly interrogate and extract meaningful biological insights from multiple research literature and comprehensive datasets, and then perform Causal AI on the derived mechanisms. The resulting output provides a unique Cancer Model System which can be used by scientists to find directly actionable insights for their drug discovery programs.

"Accelerating target discovery and validation is critical to democratizing the drug discovery industry," said **Professor Tony Sedgwick, Senior Industry Advisor**. "*Finding the right characterized targets is a hot topic in the industry today, especially in complex pathways such as the DNA Damage Response (DDR). ALaSCAdb is what research and development scientists need to accelerate their target discovery work in Ovarian (and other) cancer.*"

Access to ALaSCAdb is available on request at https://www.incubate.bio/alascadb

Access to the ALaSCA Cancer Model System will be initially available to drug discovery groups as a service provided by Incubate Bio's in-house consulting team, info@incubate.bio

++ END +++